DESTINY-GASTRIC-02
Regimen
- Experimental
- trastuzumab deruxtecan (T-DXd) 6.4 mg/kg Q3W
Population
Western HER2-positive gastric/GEJ cancer progressing on trastuzumab-containing regimen (2L)
Key finding
Confirmed ORR 42% (95% CI 30.8-53.4); mPFS 5.6 mo; mOS 12.1 mo; ILD 10% (1 grade 5)
Source: PMID 37329891
Timeline
Guideline citations
- NCCN GASTRIC (p.102)
- CSCO GASTRIC 2025 (p.104)⚠️ OCR source